Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
NCT00301522
Completed
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2010
Locations: The Lindner Clinical Trial Center, Cincinnati, Ohio +3 locations
Conditions: Coronary Stenosis
Register for Updates
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00006018
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of paclitaxel and BMS-214662 in treating patients who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2010
Locations: Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio +1 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT00251095
Terminated
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Hematology Oncology Consultants, Inc, Columbus, Ohio
Conditions: Breast Neoplasm
Register for Updates
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: Bethesda North Hospital, Cincinnati, Ohio +3 locations
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: Gynecology, Oncology, and Pelvic Surgery Associates, Inc., Columbus, Ohio
Conditions: Ovarian Neoplasm
Register for Updates